Evidence-Grounded Agentic Formulation Development in an Autonomous Laboratory

TL;DR - Andromeda 2 is an evidence-grounded agentic system that autonomously designs and tests drug formulations using computational tools and a miniaturized laboratory. For paclitaxel delivery, it substantially outperformed probabilistic optimization and design-of-experiments baselines under a matched budget.

• Achieved a 50% high-performance formulation hit rate, versus 17% for Andromeda 1 and 2% for wet-lab DoE.
• Identified 12 formulations satisfying all four target product profile objectives, compared with 6 and 0 for the baselines.
• Its median paclitaxel AUC was 70.1 mg·min/mL, versus 12.0 and 3.5 mg·min/mL.
• Structured in-house experimental evidence raised mean AUC by 34% in a controlled ablation, highlighting the value of evidence-grounded agentic reasoning.